Join the club for FREE to access the whole archive and other member benefits.

Cynata Therapeutics

Stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology.

Cynata Therapeutics Ltd (ASX: CYP) is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics and provides both a unique differentiator and an important competitive position.

Visit website: https://www.cynata.com/

 cynatatherapeutics

 cynata-therapeutics

 cynatastemcells

Details last updated 15-Jan-2020

Cynata Therapeutics News

Revolutionizing stem cell therapies with iPSC -engineered MSCS

Revolutionizing stem cell therapies with iPSC -engineered MSCS

Technology Networks - 30-Apr-2025

Cymerus™ platform enables scalable, donor-free MSC therapies for conditions like osteoarthritis

Fujifilm to test stem cells in leukemia treatment

Fujifilm to test stem cells in leukemia treatment

Nikkei - 23-Sep-2018

A company is looking to start trials for induced stem cells to fight graft vs host disease

People at Cynata Therapeutics

Mathias Kroll

Expert in biopharmaceutical research

Topics mentioned on this page:
Stem Cells, Regenerative Medicine